Purpose: Relapsed or refractory diffuse large B-cell lymphoma (rrDLBCL) is fatal in 90% of
patients, and yet little is known about its biology. Experimental Design: Using exome …

Diffuse large B-cell lymphoma (DLBCL) patients are typically treated with
immunochemotherapy containing rituximab (rituximab, cyclophosphamide …

Lack of remission or early relapse remains a major clinical issue in diffuse large B-cell
lymphoma (DLBCL), with 30% of patients failing standard of care. Although clinical factors …

Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease whose prognosis is
associated with clinical features, cell-of-origin and genetic aberrations. Recent integrative …

Despite the many efforts already spent to enumerate somatic mutations in diffuse large B‐
cell lymphoma (DLBCL), previous whole‐genome and whole‐exome studies conducted on …

PURPOSE Diffuse large B-cell lymphoma (DLBCL) is cured in more than 60% of patients,
but outcomes remain poor for patients experiencing disease progression or relapse …

Diffuse large B-cell lymphoma (DLBCL) is the most common form of lymphoma in adults.
The disease exhibits a striking heterogeneity in gene expression profiles and clinical …

Background Diffuse large B-cell lymphomas (DLBCLs) are phenotypically and genetically
heterogeneous. Gene-expression profiling has identified subgroups of DLBCL (activated B …

Purpose: Next-generation sequencing (NGS) has detailed the genomic characterization of
diffuse large B-cell lymphoma (DLBCL) by identifying recurrent somatic mutations. We set …

Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma in adults, accounting
for 35%–40% of all cases. The combination of the anti-CD20 monoclonal antibody rituximab …